Pol. Merkur. Lek (Pol. Med. J.), 2017, XLII/249: 097-100

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Stem/progenitor cells in diseases of the respiratory tract

Płusa T.

EMC Medical Institute SA – Department of Internal Medicine and Lung Disease, Hospital st. Anna in Piaseczno, Poland

Stem cells (SCs – stem cells) are characterized by plasticity and the ability to differentiate into other cell types. They are obtained from bone marrow, peripheral blood and cord blood. Mesenchymal stem cells (MSCs) shows a broad immunomodulating, increases the number of regulatory T cells (Treg), modifies the activity of T cells, dendritic cells and NK (natural killer). Direct impact on reducing the release of proinflammatory cytokines and increased release of proinflammatory cytokines. Within the respiratory tract has a number of resident stem and progenitor cells referred to as L-MSCs (lung mesenchymal stem cells) whose presence was confirmed by markers as defined in the trachea, epithelial cells and alveolar. Demonstrated the efficacy of MSCs administration in the first stage of septic shock and acute respiratory distress syndrome (ARDS – acute respiratory distress syndrome). There was a significant stimulation of repair processes, along with an improvement in lung function. Embryonic stem cells (ESCs – embryonic stem cells) are the latest addition in the treatment of congenital and acquired diseases of the airways and lung parenchyma. In patients with sarcoidosis MSCs are obtained from umbilical cord blood (PDA – placenta-derived mesenchymal-like cells) with phenotype CD34 +, CD10 +, CD105 + and CD200 +. The results of this therapy are very encouraging, and for this reason it is taken in subsequent research centers.

Key words: mesenchymal stem cells, immunomodulation, regeneration, treatment

Pol Med J, 2017; XLII (249); 97–100